TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10029210

Group type: EXPERIMENTAL
Intervention: Obsessive Compulsive Drinking Scale (OCDS)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Alcohol consumption factor from OCDS
Number of subjects: 127
Study: 8674328

Group type: EXPERIMENTAL
Intervention: Venous Arterial blood Management Protection system (VAMP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Safe Draw
Number of subjects: 40
Study: 1914031

Group type: EXPERIMENTAL
Intervention: Rheum E
Number of subjects: 30

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rheum E + Captopril
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rheum E (in 5/6 nephrectomized rats)
Number of subjects: 30
Study: 6854550

Group type: EXPERIMENTAL
Intervention: Norinyl, Norlestrin, Ovral (first study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brevicon, Lo-Ovral (second study)
Number of subjects: 0
Study: 31560131

Group type: EXPERIMENTAL
Intervention: Menstrual pads for 6 months
Number of subjects: 240

Group type: COMPARATOR
Intervention: No pads (control group)
Number of subjects: 240
Study: 31539329

Group type: EXPERIMENTAL
Intervention: Standardized Video Interview (SVI) score
Number of subjects: 321

Group type: COMPARATOR
Intervention: Traditional Interview (TI) score
Number of subjects: 321
Study: 27781372

Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet 30 mcg (SST)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 24627339

Group type: EXPERIMENTAL
Intervention: Test formulation (1 mg capsule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation (1 mg capsule)
Number of subjects: 0
Study: 25263017

Group type: EXPERIMENTAL
Intervention: Patients with eGFR <30 mL/min
Number of subjects: 5710

Group type: EXPERIMENTAL
Intervention: Overall VTE patients
Number of subjects: 5710

Group type: EXPERIMENTAL
Intervention: VTE patients with renal impairment
Number of subjects: 5710

Group type: COMPARATOR
Intervention: VTE patients with eGFR >90 mL/min
Number of subjects: 5710

Group type: COMPARATOR
Intervention: VTE patients with eGFR 60-89 mL/min
Number of subjects: 5710

Group type: COMPARATOR
Intervention: VTE patients with eGFR 45-59 mL/min
Number of subjects: 5710

Group type: COMPARATOR
Intervention: VTE patients with eGFR 30-44 mL/min
Number of subjects: 5710

Group type: COMPARATOR
Intervention: VTE patients with eGFR 15-29 mL/min
Number of subjects: 5710

Group type: COMPARATOR
Intervention: VTE patients with end-stage renal disease
Number of subjects: 5710
Study: 22846608

Group type: EXPERIMENTAL
Intervention: Sniff nasal inspiratory pressure (SNIP) in sitting position (SNIPsitt)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Forced vital capacity (FVC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ALS functional rating scale score (ALSFRS-R)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sniff nasal inspiratory pressure (SNIP) in supine position (SNIPsup)
Number of subjects: 20
Study: 19202330

Group type: EXPERIMENTAL
Intervention: B-vitamin therapy (folic acid 2 mg, vitamin B(6) 25 mg, vitamin B(12) 0.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17319775

Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush
Number of subjects: 21

Group type: COMPARATOR
Intervention: Electric toothbrush
Number of subjects: 21

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 21
Study: 15247115

Group type: EXPERIMENTAL
Intervention: 1 mg morphine hydrochloride
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 2 mg morphine hydrochloride
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 4 mg morphine hydrochloride
Number of subjects: 166

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 166
Study: 11100387

Group type: EXPERIMENTAL
Intervention: Heat stress at 44 degrees C
Number of subjects: 28
Study: 8968264

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study: 1535578

Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clarithromycin 250 mg b.i.d.
Number of subjects: 200
Study: 6367784

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg intravenously followed by 200 mg daily for three months)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395
Study: 31235169

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention provided by pharmaceutics students
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 171
Study: 30049498

Group type: EXPERIMENTAL
Intervention: Online tailored education group (n=35)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care group with online access (n=36)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care group without computer/tablet/smartphone (n=49)
Number of subjects: 120
Study: 26220357

Group type: EXPERIMENTAL
Intervention: Bilateral 8 Fr subclavian vein sheaths
Number of subjects: 61

Group type: COMPARATOR
Intervention: 16 Fr percutaneous superior vena cava cannula
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 23112075

Group type: EXPERIMENTAL
Intervention: Tricot compression bandage plus intermittent cryocompression therapy 15 times for 30 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tricot compression bandage alone
Number of subjects: 30
Study: 20105043

Group type: EXPERIMENTAL
Intervention: Preprandial insulin (PPI) (Exubera)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Basal insulin (BI) (insulin glargine)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Preprandial insulin (PPI)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Basal insulin (BI)
Number of subjects: 257
Study: 18619998

Group type: EXPERIMENTAL
Intervention: Anthropometric measurements by doctors (weight, height, BMI, waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anthropometric measurements after a one-hour training session
Number of subjects: 24
Study: 15851890

Group type: EXPERIMENTAL
Intervention: 15 mg EREM
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 20 mg EREM
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 25 mg EREM
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 14594344

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 20 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 40 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 80 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Baseline-corrected testosterone values
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Higher doses of testosterone undecanoate
Number of subjects: 45
Study: 10827390

Group type: EXPERIMENTAL
Intervention: Perflenapent emulsion
Number of subjects: 280

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 280
Study: 8794420

Group type: EXPERIMENTAL
Intervention: 0.05% all‐trans‐retinoic acid (tretinoin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6% glycolic acid
Number of subjects: 0
Study: 1379860

Group type: EXPERIMENTAL
Intervention: Chuanxiong
Number of subjects: 220

Group type: COMPARATOR
Intervention: Dextran 40
Number of subjects: 220
Study: 3900303

Group type: EXPERIMENTAL
Intervention: Metoclopramide alone (1.0 to 3.0 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoclopramide with adjunct dexamethasone (20 mg) at a fixed dose of 2.0 mg/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (metoclopramide without dexamethasone)
Number of subjects: 18
Study: 31272393

Group type: EXPERIMENTAL
Intervention: Promised HK$100 incentive upon completion
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Promised HK$200 incentive upon completion
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Prepaid HK$100 incentive plus another promised HK$100 incentive (mixed incentive)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: No incentive (control group)
Number of subjects: 1246
Study: 29197867

Group type: EXPERIMENTAL
Intervention: Topical coconut oil (5 mL/kg) twice daily for 21 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Topical coconut oil
Number of subjects: 72
Study: 27054908

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2mA, 20min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cathodal tDCS (2mA, 20min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent Anodal tDCS after Cathodal tDCS
Number of subjects: 0
Study: 24576202

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.50% (50 mL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 37
Study: 23027801

Group type: EXPERIMENTAL
Intervention: Algorithm-consistent warfarin dosing
Number of subjects: 6022
Study: 20544135

Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated CVC
Number of subjects: 172

Group type: COMPARATOR
Intervention: Conventional CVC
Number of subjects: 172
Study: 16969361

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily and Metformin 500 mg three times daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no drug therapy)
Number of subjects: 91
Study: 18245148

Group type: EXPERIMENTAL
Intervention: Etanercept (an IgG1‐TNF p75 receptor fusion protein), administered once weekly for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 15291188

Group type: EXPERIMENTAL
Intervention: Diaspirin cross-linked hemoglobin (DCLHb) solution (50 mg/kg or 35 mL for a 70-kg patient)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hetastarch (control)
Number of subjects: 10
Study: 11388055

Group type: EXPERIMENTAL
Intervention: Mammography screening with clinical examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mammography screening without clinical examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Well-designed observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized studies
Number of subjects: 0
Study: 9519099

Group type: EXPERIMENTAL
Intervention: Sulpiride (600 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8368459

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms once daily
Number of subjects: 218

Group type: COMPARATOR
Intervention: Disodium cromoglycate 5.2 mg four times daily
Number of subjects: 218
Study: 3510125

Group type: EXPERIMENTAL
Intervention: Pizotifen for 3 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 47
Study: 11369073

Group type: EXPERIMENTAL
Intervention: Conventional simulation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Virtual simulation
Number of subjects: 86
Study: 30198828

Group type: EXPERIMENTAL
Intervention: Yeast beta-glucan (900 mg daily for 16 weeks)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 29444335

Group type: EXPERIMENTAL
Intervention: Mobile application for cooperation with the teacher during clinical practicum
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard cooperation (control group)
Number of subjects: 102
Study: 26835603

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) 300 mg natalizumab
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) 300 mg natalizumab
Number of subjects: 76

Group type: COMPARATOR
Intervention: Intravenous (IV) 300 mg natalizumab
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Overall adverse events across all groups
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pharmacodynamics (PD) response
Number of subjects: 76
Study: 25409895

Group type: EXPERIMENTAL
Intervention: PRONTO simulation training
Number of subjects: 450
Study: 22539780

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (STreSS), nine 3.5 h sessions over 4 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enhanced usual care (management by primary care physician or medical specialist)
Number of subjects: 120
Study: 20679151

Group type: EXPERIMENTAL
Intervention: Milk naturally enriched in CLA (4.2%) containing c-9, t-11 providing 1.3 g/d of CLA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk enriched with a 4.2% synthetic mixture of t-10, c-12 and c-9, t-11 CLA isomers providing 1.3 g/d of CLA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated milk (control) providing 0.2 g/d CLA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk enriched with CLA (both types)
Number of subjects: 0
Study: 17564282

Group type: EXPERIMENTAL
Intervention: 800 mcg nebulized beclomethasone dipropionate once daily (o.d. group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 400 mcg nebulized beclomethasone dipropionate twice daily (b.i.d. group)
Number of subjects: 65
Study: 16109532

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine method (Control)
Number of subjects: 70
Study: 12441019

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 0
Study: 10419077

Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol 5/50 mg
Number of subjects: 212

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 212
Study: 7759064

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose level clamped at 12.2 mmol/l for 4 hours by infusing 20% glucose solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control (isotonic saline infusion over 4 hours)
Number of subjects: 0
Study: 2185694

Group type: EXPERIMENTAL
Intervention: KRN 8601 at 50 micrograms/m2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: KRN 8601 at 100 micrograms/m2
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control phase without KRN 8601 treatment
Number of subjects: 36
Study: 311515

Group type: EXPERIMENTAL
Intervention: Surgical treatment (aortocoronary bypass surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study: 30972934

Group type: EXPERIMENTAL
Intervention: Liraglutide therapy for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Type 2 diabetic subjects
Number of subjects: 0
Study: 29693429

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (5 mmol per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 26635348

Group type: EXPERIMENTAL
Intervention: Beetroot juice (∼8 mmol NO3 (‐))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Beetroot juice + mouthwash (Beet+MW)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (nitrate‐depleted Beet)
Number of subjects: 8
Study: 25046624

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg twice daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 56
Study: 22417277

Group type: EXPERIMENTAL
Intervention: Michigan Neuropathy Screening Instrument (MNSI) questionnaire
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Michigan Neuropathy Screening Instrument (MNSI) examination
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: New scoring algorithms for MNSI
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Confirmed clinical neuropathy
Number of subjects: 1184
Study: 20157905

Group type: EXPERIMENTAL
Intervention: Multi-component sleep therapy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic sleep hygiene education
Number of subjects: 0
Study: 17286094

Group type: EXPERIMENTAL
Intervention: ECC exercise program
Number of subjects: 32

Group type: COMPARATOR
Intervention: TRAD exercise program
Number of subjects: 32
Study: 16083948

Group type: EXPERIMENTAL
Intervention: Intermittent self-catheterisation (ISC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supra-pubic catheterisation (SPC)
Number of subjects: 40
Study: 12690368

Group type: EXPERIMENTAL
Intervention: Subtenons lidocaine injection (1 mL of 2% lidocaine)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Subtenons lidocaine injection
Number of subjects: 31
Study: 10965640

Group type: EXPERIMENTAL
Intervention: Internet-delivered intervention (Student Bodies [SB])
Number of subjects: 76

Group type: COMPARATOR
Intervention: Classroom-delivered intervention (Body Traps [BT])
Number of subjects: 76

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 76
Study: 8791969

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Pantoprazole 80 mg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both dosing schedules
Number of subjects: 192
Study: 1620911

Group type: EXPERIMENTAL
Intervention: Modified formulation of inhaled salbutamol using a new inhaler device
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional salbutamol
Number of subjects: 11

Group type: COMPARATOR
Intervention: New inhaler device (Rotahaler)
Number of subjects: 11
Study: 6391830

Group type: EXPERIMENTAL
Intervention: Trazodone (100 to 400 mg daily)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mianserin (30 to 120 mg daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 111
Study: 30282447

Group type: EXPERIMENTAL
Intervention: R-CHOP-14 (administered every 2 weeks)
Number of subjects: 702

Group type: COMPARATOR
Intervention: R-CHOP-21 (administered every 3 weeks)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: R-CHOP-14 and R-CHOP-21
Number of subjects: 702
Study: 29214483

Group type: EXPERIMENTAL
Intervention: CBT + active tDCS
Number of subjects: 192

Group type: COMPARATOR
Intervention: CBT + sham‐tDCS
Number of subjects: 192

Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 192
Study: 26271678

Group type: EXPERIMENTAL
Intervention: Heavy load (25 kg backpack)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unloaded condition (no backpack)
Number of subjects: 15
Study: 24491414

Group type: EXPERIMENTAL
Intervention: 1.5 ml kg(‐1) of 0.15% ropivacaine with 0.1 mg kg(‐1) dexamethasone (Group D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1.5 ml kg(‐1) of 0.15% ropivacaine (Group C)
Number of subjects: 80
Study: 22348439

Group type: EXPERIMENTAL
Intervention: DHA meal (high-oleic sunflower oil enriched with 4.7 g of DHA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EPA meal (high-oleic sunflower oil enriched with 4.7 g of EPA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control meal (high-oleic sunflower oil only)
Number of subjects: 22
Study: 20201666

Group type: EXPERIMENTAL
Intervention: Retreat group (23 residents)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (26 residents)
Number of subjects: 49
Study: 17494795

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 14
Study: 16153508

Group type: EXPERIMENTAL
Intervention: EDPR gradient > 5.0 mm Hg
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: EDPR gradient
Number of subjects: 741
Study: 12041862

Group type: EXPERIMENTAL
Intervention: Modified TCu380A insertion technique (shortened applicator by 1.5 cm)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Unmodified TCu380A insertion technique
Number of subjects: 169
Study: 9710393

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg x kg(‐1) x min(‐1))
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fentanyl (2 microg x kg(‐1) x min(‐1))
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 23
Study: 7996626

Group type: EXPERIMENTAL
Intervention: Unilateral vestibular neurectomy
Number of subjects: 6
Study: 3179579

Group type: EXPERIMENTAL
Intervention: Test meal at 20 degrees C
Number of subjects: 8

Group type: COMPARATOR
Intervention: Test meal at 37 degrees C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Test meal at 4 degrees C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Test meal at 55 degrees C
Number of subjects: 8
Study: 30446424

Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional suture
Number of subjects: 96
Study: 30369379

Group type: EXPERIMENTAL
Intervention: Bupivacaine (20ml/50mg of 0.25%)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 94
Study: 26201934

Group type: EXPERIMENTAL
Intervention: Naso-jejunal (NJ) fluid resuscitation using oral hydration solution (ORS: 20 ml/kg bolus and then 3 mL/kg/h)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intravenous (IV) fluid resuscitation using Ringer Lactate (RL infusion at same rate)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Naso-jejunal (NJ) fluid resuscitation using oral hydration solution (ORS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intravenous (IV) fluid resuscitation using Ringer Lactate (RL)
Number of subjects: 49
Study: 25440210

Group type: EXPERIMENTAL
Intervention: Occiput-atlas-axis global manipulation (OAA)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of both techniques
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Suboccipital soft tissue inhibition
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 22795809

Group type: EXPERIMENTAL
Intervention: Oral ferrous bisglycinate chelate, 28 mg per day for 20 days, then 14 mg per day for 40 days (12 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral ferrous sulfate, 105 mg per day for 60 days (12 patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) related to treatments
Number of subjects: 24
Study: 20587101

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Supplemental oxygen
Number of subjects: 28